First american study of trimetazidine (FAST) / Primer estudio americano de trimetazidine (FAST)

ABSTRACT

Fitty one patients with ischemic heart disease were studied through a multicenter, placebo, double blind design, under the treatment of trimetazidine. This compound protects the coenzyme NAD action at the respiratory cellular level and mantains the energetic production of ATP, reduces acidosis and decreases the formation of free radicals. Trimetazidine was administered at the oral dose of 60 mg daily. Two groups of subjects entered to the study: normotensive and hypertensives, Trimetazidine was effective to reduce anginal crisis and increased the duration of exercise test in hypertensive subjects. A similar effectiveneses was observed in normotansives